Immediate Treatment and Mechanical Support
At a Glance
Giant cell myocarditis is treated urgently at an advanced heart failure center with combined immune-suppressing medicines. If the heart cannot pump enough blood, VA-ECMO, Impella, or a ventricular assist device can support circulation while recovery or transplantation is considered.
Because Giant Cell Myocarditis (GCM) is a severe autoimmune condition in the heart, the primary goal of treatment is to suppress the immune response as rapidly as possible [1]. This requires a combination of powerful medications and, in many cases, mechanical machines that take over the work of the heart while the medications have time to work [2][3].
Specialist-Directed Combination Immunosuppression
Because GCM is exceptionally rare, there is no single, universally proven protocol based on large randomized trials. Instead, care is guided by specialized heart failure teams using combination immunosuppression. The exact drugs, doses, sequence, and duration will vary based on your clinical situation [1].
A commonly used specialist approach involves:
- Corticosteroids: You will likely start with intravenous “pulse” doses of steroids (like methylprednisolone) to quickly blunt the immune attack, followed by a long, careful taper of oral pills [4][5].
- Calcineurin Inhibitors (Cyclosporine or Tacrolimus): These drugs specifically suppress the T-cells from attacking your heart muscle [1]. Because these medications can be hard on the kidneys, your team will check your blood frequently to ensure the “trough level” (the amount of drug in your system) is safe and effective [6][7].
- Antimetabolites (Mycophenolate Mofetil or Azathioprine): A third drug is often added to the mix to provide a long-term “shield” against the immune system [4].
In very severe cases or if the heart is not responding, doctors may use Antithymocyte Globulin (ATG)—a potent intravenous therapy that rapidly clears T-cells from the body, though its use is individualized rather than routine [7][8].
Medication Safety: These intense treatments carry significant risks. Suppressing your immune system makes you highly vulnerable to infections; you may be prescribed specific preventative antibiotics, and any fever must be reported immediately. Additionally, drugs like cyclosporine can cause kidney strain, and steroids can raise blood sugar and blood pressure. You must never start, stop, or taper these medications without explicit instructions from your specialist team.
Mechanical Circulatory Support (MCS)
If your heart is in cardiogenic shock (meaning it cannot pump enough blood to your organs), your care team may use mechanical support [2]. These machines are often used as a “bridge”—a temporary solution while waiting for the heart to recover (Bridge to Recovery) or for a transplant to become available (Bridge to Transplant) [3][9].
- VA-ECMO: This machine (Veno-Arterial Extracorporeal Membrane Oxygenation) acts as an external heart and lung. It pulls blood out of the body, adds oxygen, and pumps it back in [10][11].
- Impella: A tiny pump inserted into the heart through a tube in the leg or chest to help push blood forward [12].
- VAD/BiVAD: A Ventricular Assist Device is a surgically implanted pump that supports either the left side of the heart (LVAD), the right side (RVAD), or both (BiVAD) [3][13]. In small retrospective series, a high percentage of GCM patients needing mechanical support required a BiVAD because the disease often affects both sides of the heart [3].
Understanding the Risks: Mechanical support involves major risks, including severe bleeding, blood clots, stroke, and a very high risk of infection. In one selected cohort of GCM patients on support, 80% experienced an infection [10]. Furthermore, requiring support or undergoing a transplant evaluation does not guarantee listing for a donor heart. The decision to use these therapies involves careful discussion of the goals of care with your team.
Why Specialized Centers Matter
GCM is too rare and aggressive for a standard community hospital to manage alone. It is critical that you are treated at an Advanced Heart Failure and Transplant Center [10][14]. These centers offer specialized pathologists who can identify the disease accurately [15], surgical teams to manage MCS 24/7 [2], and direct access to transplant evaluation if the heart muscle is too damaged to recover [16]. While the treatment is aggressive, combination therapy managed at expert centers aims to keep you stable while the medications give your heart a chance to heal [9].
Common questions in this guide
What is the usual first treatment for giant cell myocarditis?
When is mechanical heart support needed in GCM?
What are the main risks of immunosuppressive treatment?
Why should GCM be treated at an advanced heart failure center?
How do doctors decide between waiting for heart recovery and heart transplant?
How are side effects from GCM medicines monitored?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific combination of immunosuppressants are you recommending for my case, and why was this combination chosen for me?
- 2.Does this facility have on-site capabilities for advanced mechanical support like VA-ECMO or BiVADs?
- 3.How often will my kidney function, blood sugar, and drug trough levels be checked to monitor for medication side effects?
- 4.At what point will we decide if I am a candidate for a heart transplant or if we are waiting for my heart to recover (bridge to recovery)?
- 5.What specific infection precautions should we be taking while my immune system is heavily suppressed?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Giant cell myocarditis: from immune pathogenesis to contemporary management.
Vosko I, Wallner M
Heart failure reviews 2026; (31(1)).
PMID: 42624936 - 2
Diagnosis and Treatment of Acute Myocarditis: A Review.
Ammirati E, Moslehi JJ
JAMA 2023; (329(13)):1098-1113 doi:10.1001/jama.2023.3371.
PMID: 37014337 - 3
Outcomes of Mechanical Circulatory Support for Giant Cell Myocarditis: A Systematic Review.
Patel PM, Saxena A, Wood CT, et al.
Journal of clinical medicine 2020; (9(12)) doi:10.3390/jcm9123905.
PMID: 33271929 - 4
Successful Triple Combination Immunosuppressive Therapy with Prednisolone, Cyclosporine, and Mycophenolate Mofetil to Treat Recurrent Giant Cell Myocarditis.
Akita T, Mori S, Onishi A, et al.
Internal medicine (Tokyo, Japan) 2019; (58(14)):2035-2039 doi:10.2169/internalmedicine.2471-18.
PMID: 30918193 - 5
Complete remission of giant cell myocarditis by prednisolone monotherapy: A case with mild inflammation demonstrated by mismatch between T2-high intensity areas and late gadolinium enhancement.
Soma T, Kinjo T, Goto S, et al.
Journal of cardiology cases 2024; (29(4)):182-185 doi:10.1016/j.jccase.2023.12.007.
PMID: 38646085 - 6
Heart Transplantation for Giant Cell Myocarditis: A Case Series.
Vaidya GN, Czer LSC, Luthringer D, et al.
Transplantation proceedings 2021; (53(1)):348-352 doi:10.1016/j.transproceed.2020.10.047.
PMID: 33384178 - 7
Usefulness of Rabbit Anti-thymocyte Globulin in Patients With Giant Cell Myocarditis.
Suarez-Barrientos A, Wong J, Bell A, et al.
The American journal of cardiology 2015; (116(3)):447-51.
PMID: 26048854 - 8
Two case reports of fulminant giant cell myocarditis treated with rabbit anti-thymocyte globulin.
Bartz-Overman C, Li S, Puligandla B, et al.
European heart journal. Case reports 2024; (8(4)):ytae128 doi:10.1093/ehjcr/ytae128.
PMID: 38567279 - 9
Mechanical Circulatory Support Combined With Immunosuppression for the Treatment of Giant Cell Myocarditis - A Single-Center Experience in Japan.
Nakajima-Doi S, Mochizuki H, Iwasaki K, et al.
Circulation journal : official journal of the Japanese Circulation Society 2020; (84(5)):815-819 doi:10.1253/circj.CJ-19-0847.
PMID: 32173690 - 10
Fulminant giant-cell myocarditis on mechanical circulatory support: Management and outcomes of a French multicentre cohort.
Montero S, Aissaoui N, Tadié JM, et al.
International journal of cardiology 2018; (253()):105-112 doi:10.1016/j.ijcard.2017.10.053.
PMID: 29306448 - 11
Characteristics of histologically proven fulminant myocarditis managed with venoarterial extracorporeal membrane oxygenation: A post-hoc analysis of a Japanese nationwide study.
Sawada K, Ogata S, Kanaoka K, et al.
Journal of cardiology 2026; (87(4)):332-339 doi:10.1016/j.jjcc.2025.08.009.
PMID: 40865716 - 12
Giant cell myocarditis treated with long-term multi-modal care with multiple mechanical circulatory support: case report.
Shingu M, Tatsuya N, Oga Y, et al.
Oxford medical case reports 2026; (2026(7)):omag110 doi:10.1093/omcr/omag110.
PMID: 42422271 - 13
Treatment of Fulminant Giant Cell Myocarditis Associated with Polymyositis Using a Left Ventricular Assist Device and Subsequent Corticosteroid and Immunosuppressive Therapy Leading to Remission.
Ooka J, Tanaka H, Hatani Y, et al.
Internal medicine (Tokyo, Japan) 2017; (56(16)):2155-2158 doi:10.2169/internalmedicine.8639-16.
PMID: 28781324 - 14
Giant cell myositis and myocarditis revisited.
Oflazer P
Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2020; (39(4)):302-306 doi:10.36185/2532-1900-033.
PMID: 33458585 - 15
Idiopathic giant cell myocarditis or cardiac sarcoidosis? A retrospective audit of a nationwide case series.
Ekström K, Räisänen-Sokolowski A, Lehtonen J, et al.
ESC heart failure 2020; (7(3)):1362-1370 doi:10.1002/ehf2.12725.
PMID: 32343481 - 16
Heart Transplantation in Giant Cell Myocarditis: Analysis of the United Network for Organ Sharing Registry.
Elamm CA, Al-Kindi SG, Bianco CM, et al.
Journal of cardiac failure 2017; (23(7)):566-569 doi:10.1016/j.cardfail.2017.04.015.
PMID: 28449952
This page explains treatment and mechanical support for giant cell myocarditis for informational purposes only and does not replace medical advice. Medication and transplant decisions must be made with an advanced heart failure specialist.
Get notified when new evidence is published on Giant cell myocarditis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.